-
Merck/Ridgeback Biotherapeutics' COVID-19 Antiviral Shows Promise
Monday, March 8, 2021 - 7:54am | 302Read More...Merck & Co Inc (NYSE: MRK) and its collaborating partner Ridgeback Biotherapeutics LP reported preliminary results from Phase 2a study evaluating molnupiravir, an experimental antiviral drug against COVID-19. The antiviral has shown positive effects with a...
-
Gemini Therapeutics Completes 60 Patients Enrollment In Lead Candidate Mid-Stage Study In Dry AMD
Wednesday, February 10, 2021 - 1:07pm | 154Read More...Gemini Therapeutics Inc (NASDAQ: GMTX) concludes enrollment in its Phase 2a ReGAtta study evaluating GEM103, a recombinant human complement factor H (CFH), in dry Age-related macular degeneration (AMD) patients with CFH loss-of-function gene variants. The 60-subject trial is...
-
Importance Of Phase 2 Trials
Monday, July 25, 2016 - 9:14am | 515Read More...Healthcare and pharmaceutical companies begin evaluating a drug they wish to sell to the public through a series of clinical trials. A Phase I trial consists of a company testing its drug or therapy on a small group of 20 to 100 healthy volunteers. Chiara Russo, a stock analyst for Cantor...
